Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides

被引:150
作者
Schirmer, A [1 ]
Kennedy, J [1 ]
Murli, S [1 ]
Reid, R [1 ]
Santi, DV [1 ]
机构
[1] Kosan Biosci, Hayward, CA 94545 USA
关键词
B-RAF V600E; hypothemycin; irreversible kinase inhibitor; Michael adduct;
D O I
10.1073/pnas.0600445103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Resorcylic acid lactones containing a cis-enone are susceptible to Michael addition reactions and are potent inhibitors of several protein kinases. A structural-bioinformatics analysis identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not. Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue. Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets containing the conserved Cys were inhibited. Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochemical studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation. Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates. Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2. Among cells without mitogen receptor targets, those harboring an ERK pat way-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin. Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-containing targets MEK3/6 and TGF-beta-activated kinase 1 and of the JNK/SAPK (cJun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.
引用
收藏
页码:4234 / 4239
页数:6
相关论文
共 28 条
[1]   Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation [J].
Camacho, R ;
Staruch, MJ ;
DaSilva, C ;
Koprak, S ;
Sewell, T ;
Salituro, G ;
Dumont, FJ .
IMMUNOPHARMACOLOGY, 1999, 44 (03) :255-265
[2]   Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].
Cohen, MS ;
Zhang, C ;
Shokat, KM ;
Taunton, J .
SCIENCE, 2005, 308 (5726) :1318-1321
[3]  
Copeland R. A., 2000, ENZYMES PRACTICAL IN, P318
[4]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[5]   Production of a family of kinase-inhibiting lactones from fungal fermentations [J].
Dombrowski, A ;
Jenkins, R ;
Raghoobar, S ;
Bills, G ;
Polishook, J ;
Peláez, F ;
Burgess, B ;
Zhao, A ;
Huang, LY ;
Zhang, Y ;
Goetz, M .
JOURNAL OF ANTIBIOTICS, 1999, 52 (12) :1077-1085
[6]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336
[7]  
Fersht A., 1984, ENZYME STRUCTURE MEC
[8]   Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor [J].
Fry, DW ;
Bridges, AJ ;
Denny, WA ;
Doherty, A ;
Greis, KD ;
Hicks, JL ;
Hook, KE ;
Keller, PR ;
Leopold, WR ;
Loo, JA ;
McNamara, DJ ;
Nelson, JM ;
Sherwood, V ;
Smaill, JB ;
Trumpp-Kallmeyer, S ;
Dobrusin, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :12022-12027
[9]   Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma [J].
Garraway, LA ;
Widlund, HR ;
Rubin, MA ;
Getz, G ;
Berger, AJ ;
Ramaswamy, S ;
Beroukhim, R ;
Milner, DA ;
Granter, SR ;
Du, JY ;
Lee, C ;
Wagner, SN ;
Li, C ;
Golub, TR ;
Rimm, DL ;
Meyerson, ML ;
Fisher, DE ;
Sellers, WR .
NATURE, 2005, 436 (7047) :117-122
[10]  
GIESE N, 1998, Patent No. 5728726